Choosing Antipsychotic Maintenance Therapy - A Naturalistic Study

Antipsychotic maintenance treatment is essential for preventing relapses of schizophrenia, but the variety of available antipsychotics may complicate the choice of drug. The aim of our naturalistic one-year follow-up study was to find out the factors predicting the choice of antipsychotics in discharged patients with schizophrenia or schizoaffective disorder and the predictors of one-year rehospitalization. The patients were receiving oral or depot classical antipsychotics or atypical agents clozapine or risperidone. Symptoms were assessed with Present State Examination. Included were 447 patients (202 males and 245 females) with a mean age of 39.1 years and 5.9 previous hospitalizations. The majority of patients (n = 322) were receiving depot antipsychotics and 43 were prescribed atypical agents. Two predictive models were built using the logistic regression analysis. Previously prescribed depot antipsychotics were positively related to further depot use, while patients who left the hospital against medical advice and those with slowness of speech at admission were less likely to receive depot drugs. On the other hand, previously used atypical antipsychotics and longer hospitalization predicted further use of atypical agents while patients discharged to community care facilities or nursing homes and those with more frequent previous hospitalizations were less likely to receive atypical agents. The Cox survival analysis showed the following one-year rehospitalization risk factors: diagnosis of schizoaffective disorder, frequent previous hospitalizations, inappropriate behavior, and oral classical antipsychotics versus depot or atypical agents. This study may yield some insight into the decision-making process in everyday clinical work regarding the choice of antipsychotic maintenance medication and its influence on rehospitalization rate.

Reference

• 1 American Psychiatric Association . Practice guideline for the treatment of patients with schizophrenia.  Am J Psychiatry. 1997;  154 (Suppl.) 1-63
• 2 Balon R. The underutilization of depot neuroleptic therapy.  J Clin Psychiatry. 1994;  55 39
• 3 Barnas C, Stuppäck C, Miller C H, Haring C, Sperner-Unterweger B, Fleischhacker W W.. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol.  Int Clin Psychopharmacol. 1992;  7 23-27
• 4 Barnes T R, Curson D A. Long-term depot antipsychotics. A risk-benefit assessment.  Drug Saf. 1994;  10 464-479
• 5 Borison R L. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics.  J Clin Psychopharmacol. 1995;  15 (Suppl. 1) 24
• 6 Bourin M, Venisse J L, Lecuyer F. Resultats d'une enque^te sur l'utilisation en psychiatrie des neurole¿ptiques a action prolonge¿e.  Encephale. 1990;  16 363-369
• 7 Burnett P L, Galletly C A, Moyle R J, Clark C R. Low-dose depot medication in schizophrenia.  Schizophr Bull. 1993;  19 155-164
• 8 Chiles J A, Miller A L, Crismon M L, Rush A J, Krasnoff A S, Shon S S. The Texas medication algorithm project: development and implementation of the schizophrenia algorithm.  Psychiatr Serv. 1999;  50 69-74
• 9 Davis J M, Kane J M, Marder S R, Brauzer B, Gierl B, Schooler N, Casey D E, Hassan M. Dose response of prophylactic antipsychotics.  J Clin Psychiatry. 1993;  54 (Suppl.) 24-30
• 10 Davis J M, Matalon L, Watanabe M D, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy.  Drugs. 1994;  47 741-773
• 11 Dunn C J, Fitton A. Sertindole: new drug profile.  CNS Drugs. 1996;  5 224-230
• 12 Fleischhacker W W, Hummer M. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes.  Drugs. 1997;  53 915-929
• 13 Flynn S W, MacEwan G W, Altman S, Kopala L C, Fredrikson D H, Smith G N, Honer W G. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia.  Pharmacopsychiatry. 1998;  31 25-29
• 14 Glazer W M, Kane J M. Depot neuroleptic therapy: an underutilized treatment option.  J Clin Psychiatry. 1992;  53 426-433
• 15 Hirsch S R, Jolley A G, Barnes T R, Liddle P F, Curson D A, Patel A, York A, Bercu S, Patel M. Dysphoric and depressive symptoms in chronic schizophrenia.  Schizophr Res. 1989;  2 259-264
• 16 Hirschberg E. Long persisting drug-induced parkinsonism - a case report.  Pharmacopsychiatry. 1987;  20 278
• 17 Kane J M, Honigfeld G, Singer J, Meltzer H Y, and the Clozaril Collaborative Study Group. Clozapine for the treatment resistant schizophrenia: a double blind comparison study with chlorpromazine.  Arch Gen Psychiatry. 1988;  45 789-796
• 18 Kane J M, Aguglia E, Altamura A C, Ayuso Gutierrez J L, Brunello N, Fleischhacker W W, Gaebel W, Gerlach J, Guelfi J D, Kissling W, Lapierre Y D, Lindström E, Mendlewicz J, Racagni G, Carulla L S, Schooler N R. Guidelines for depot antipsychotic treatment in schizophrenia.  Eur Neuropsychopharmacol. 1998;  8 55-66
• 19 Kissling W. Compliance, quality assurance and standards for relapse prevention in schizophrenia.  Acta Psychiatr Scand. 1994;  89 (Suppl. 382) 16-24
• 20 Lane H-Y, Liu C-C, Chang W-H. Risperidone for exclusively negative symptoms.  Am J Psychiatry. 1999;  156 335
• 21 Marder S R. The role of dosage and plasma levels in neuroleptic relapse prevention.  Acta Psychiatr Scand. 1994;  89 (Suppl. 382) 25-27
• 22 Martyns-Yellowe I S. The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment.  West Afr J Med. 1994;  13 200-203
• 23 Meltzer H Y, Hippius H. The assessment and management of treatment-resistant schizophrenia in perspective.  Eur Psychiatry. 1995;  10 (Suppl. 1) 3
• 24 Miyaoka H, Kamijima K. Japanese psychiatrists' impressions on the efficacy and safety of seven antipsychotic drugs.  Pharmacopsychiatry. 1997;  30 276
• 25 Nuechterlein K H, Dawson M E, Ventura J, Gitlin M, Subotnik K L, Snyder K S, Mintz J, Bartzokis G. The vulnerability/stress model of schizophrenic relapse: a longitudinal study.  Acta Psychiatr Scand. 1994;  89 (Suppl. 382) 58-64
• 26 Nyberg S, Farde L, Halldin C. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.  Arch Gen Psychiatry. 1997;  54 953-958
• 27 Pabis D J, Dorson P G, Crismon M L. Evaluation of inpatient depot antipsychotic prescribing.  Ann Pharmacother. 1996;  30 1381-1386
• 28 Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication.  Acta Psychiatr Scand. 1997;  95 464-468
• 29 Remington G J, Adams M E. Depot neuroleptic therapy: clinical considerations.  Can J Psychiatry. 1995;  40 (Suppl. 1) -11
• 30 Schwartz J T, Brotman A W. A clinical guide to antipsychotic drugs.  Drugs. 1992;  44 981-992
• 31 Salvador-Carulla L, Rodriguez-Blázquez C. Psychosocial modifiers of drug prescription: the hidden face of pharmacology?.  Pharmacoepidemiol Drug Saf. 1998;  7 23-30
• 32 Silverstone T. Clinically relevant differences between antipsychotic compounds.  Acta Psychiatr Scand. 1990;  82 (Suppl. 358) 88-91
• 33 Solgaard T, Kistrup K, Aaes-Jorgensen T, Gerlach J. Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients. Minimum effective dose and corresponding serum levels.  Pharmacopsychiatry. 1994;  27 119-123
• 34 Soni S D, Sampath G, Shah A, Krska J. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.  Acta Psychiatr Scand. 1992;  85 354-359
• 35 Soni S D, Gaskell K, Reed P. Factors affecting rehospitalisation rates of chronic schizophrenic patients living in the community.  Schizophr Res. 1994;  12 169-177
• 36 Tavcar R, Dernovsek M Z. Recidivism in Slovenia.  Psychiatr Serv. 1997;  48 955-956
• 37 Thomas C S, Lewis S. Which atypical antipsychotic?.  Br J Psychiatry. 1998;  172 106-109
• 38 Tollefson G D. Olanzapine: novel antipsychotic with a broad spectrum profile.  Neuropsychopharmacology. 1994;  10 805
• 39 Trenckmann U. Wirkungen und Nebenwirkungen der Depot-Neuroleptika im Erleben des Patienten.  Psychiatr Prax. 1990;  17 184-187
• 40 Tuninger E, Levander S. Large variations of plasma levels during maintenance treatment with depot neuroleptics.  Br J Psychiatry. 1996;  169 618-621
• 41 Tuninger E, Levander S. Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients.  Acta Psychiatr Scand. 1997;  96 347-353
• 42 Viguera A C, Baldessarini R J, Hegarty J D, van Kammen D P, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.  Arch Gen Psychiatry. 1997;  54 49-55
• 43 Voirol P, Robert P A, Meister P, Oros L, Baumann P. Psychotropic drug prescription in a psychiatric university hospital.  Pharmacopsychiatry. 1999;  32 29-37
• 44 Zvan V. Nacela vzdrzevalne nevrolepticne terapije psihoz.  Zdravstveno Varstvo. 1989;  28 335-341
• 45 Wei F C, Jann M W, Lin H N, Piao Chen C, Chang W H. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.  J Clin Psychiatry. 1996;  57 298-302
• 46 Weiden P, Schooler N R, Severe J B, Lee J H, Schulz S C. Stabilization and depot neuroleptic dosages.  Psychopharmacol Bull. 1993;  29 269-275
• 47 Weiden P, Rapkin B, Zygmunt A, Mott T, Goldman D, Frances A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen.  Psychiatr Serv. 1995;  46 1049-1054
• 48 Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia.  J Clin Psychiatry. 1996;  57 (Suppl. 11) 53-60
• 49 Wing J K, Cooper J E, Sartorius N. Measurement and classification of psychiatric symptoms. Cambridge; University Press 1974